TX HB 3717
died on adjournmentRelating to the establishment of a grant program to fund the United States Food and Drug Administration's drug development trials with ibogaine for the purpose of securing the administration's approval as a medication for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy.
Texas · 89th Legislature (2025 Regular Session) · lower
Quick answers
Did TX HB 3717 pass?
No. TX HB 3717 died when the 89th Legislature (2025 Regular Session) adjourned without final action on it. Bills that die this way are sometimes reintroduced in a later session. Latest recorded action (2025-05-12): Laid on the table subject to call
What is TX HB 3717 about?
TX HB 3717 is a bill in the 89th Legislature (2025 Regular Session) titled “Relating to the establishment of a grant program to fund the United States Food and Drug Administration's drug development trials with ibogaine for the purpose of securing the administration's approval as a medication for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy.”.
Who sponsors TX HB 3717?
Harris, Leach, Phelan and 2 others are the primary sponsors of TX HB 3717, joined by 29 cosponsors.
- Introduced
- 2025-03-26
- Latest action
- 2025-05-12 — Laid on the table subject to call
- Bill type
- bill
- Last updated
- —
Subjects
Sponsors
- Harrisprimary
- Leachprimary
- Phelanprimary
- Orrprimary
- VanDeaverprimary
- Alderscosponsor
- Barrycosponsor
- Bell, Keithcosponsor
- Buckleycosponsor
- Caincosponsor
- Davis, Aichacosponsor
- Gámezcosponsor
- Garcia, Joseycosponsor
- Gerdescosponsor
- Hefnercosponsor
- LaHoodcosponsor
- Lalanicosponsor
- Leo Wilsoncosponsor
- Lopez, Janiecosponsor
- Lujancosponsor
- McLaughlincosponsor
- Metcalfcosponsor
- Morales Shawcosponsor
- Morales, Eddiecosponsor
- Olcottcosponsor
- Piersoncosponsor
- Raymondcosponsor
- Schoolcraftcosponsor
- Shofnercosponsor
- Swansoncosponsor
- Tinderholtcosponsor
- Vasutcosponsor
- Villaloboscosponsor
- Zwienercosponsor
Committees
Not provided by source.
Action timeline
2025-03-04
Filed
filing
2025-03-26
Read first time
introduction,reading-1
2025-03-26
Referred to Public Health
referral-committee
2025-04-07
Considered in public hearing
2025-04-07
Testimony taken/registration(s) recorded in committee
2025-04-07
Left pending in committee
2025-04-14
Considered in public hearing
2025-04-14
Reported favorably w/o amendment(s)
committee-passage,committee-passage-favorable
2025-04-23
Comte report filed with Committee Coordinator
filing
2025-04-23
Committee report distributed
2025-04-25
Committee report sent to Calendars
2025-04-30
Considered in Calendars
2025-05-02
Placed on General State Calendar
2025-05-05
Read 2nd time
reading-2
2025-05-05
Postponed
2025-05-07
Laid out as postponed business
2025-05-07
Postponed
2025-05-09
Laid out as postponed business
2025-05-09
Postponed
2025-05-12
Laid out as postponed business
2025-05-12
Postponed
2025-05-12
Companion considered in lieu of
2025-05-12
Laid on the table subject to call
deferral
Versions
Documents
- text/html
- application/pdf
- text/html
- application/pdf
- text/html
- text/html
- text/html(no extracted text yet)
Votes
Not provided by source.
Related bills
- Companion bill: SB 2308
Official source
Attribution
Data from openstates_bulk_csv, retrieved 2026-07-24T05:33:51.767464Z
Inspect retained evidence for changes recorded after evidence tracking began:
Use this data
Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=TX&identifier=HB 3717. See the API docs or the MCP server for AI assistants.
Known limitations
- Sponsor party and chamber affiliation are not yet captured by this API.
- Committee referrals are not yet captured.
- Some documents have no extracted text yet, so version comparison may be limited.
See the methodology page for data sources and limitations.